ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI to Ask Cancer Panel, NCAB, to Help Respond To Request for Review Of National Cancer Program

December 4, 1992

Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL

December 31, 2010

Interview: “People don’t understand Clinical Trials.

September 5, 1997

Omnibus bill recissions would cut $28 million from NCI FY04 budget.

January 9, 2004

Solomon Gard Loses Final Cancer Battle

February 12, 1982

Biostatistician Thomas Fleming Warns Against Approval of Provenge.

May 4, 2007